PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Janssen’s psoriasis med Tremfya scores long-term safety and efficacy data

Janssen has announced new open-label extension data for Tremfya, with the treatment continuing to show high rates of skin clearance through nearly five years in moderate to severe plaque psoriasis.

In the phase III VOYAGE 1 study, Tremfya (guselkumab) also showed no new safety signals in the plaque psoriasis patients. At week 252 in the combined Tremfya group, 84% of patients achieved a psoriasis area severity index (PASI) 90 response – representing a 90% improvement in the PASI score compared to baseline.

In addition, 82.4% of patients also achieved an investigator’s global assessment (IGA) score of 0 (clear) or 1 (almost clear). Safety outcomes were observed through 264 weeks with no new safety signals observed.

“We are excited to share these data demonstrating Tremfya’s ability to help adults living with moderate to severe plaque psoriasis by providing sustained rates of clearance through nearly five years for the majority of patients,” said Lloyd Miller, vice president, Immunodermatology Disease Area Leader, Janssen Research & Development.

“With remission as the ultimate goal, we are committed to continuing to apply the best science and disease insights to advancing therapies that improve the lives of patients,” he added.

Tremfya is a fully human monoclonal antibody that selectively binds to p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is believed to be an important driver of the immune-mediated inflammatory diseases, including psoriasis.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026